Area of research
Oncology · Molecular Biology
Research interest
Research interests include PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics, DNA Repair Mechanisms, and BRCA gene mutations in cancer.
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor